Press Releases and Events

PRESS RELEASES

Press Release | July 10, 2024

Crinetics Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | June 18, 2024

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

READ MORE
Press Release | June 10, 2024

Crinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | June 3, 2024

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

READ MORE
Press Release | June 3, 2024

Crinetics Presents New Data at ENDO 2024 that Increases that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

READ MORE
Press Release | May 30, 2024

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

READ MORE
Press Release | May 22, 2024

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

READ MORE
Press Release | May 10, 2024

Crinetics Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | May 9, 2024

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

READ MORE
Press Release | May 8, 2024

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

READ MORE
8 / 25